Last reviewed · How we verify

NCT02970799

Tear Production by Nasal Neurostimulation Compared to Active Control

Completed NA Results posted Last updated 19 October 2021
What this trial tests

NA trial testing Intranasal Neurostimulator in Dry Eye in 27 participants. Completed in 31 October 2016.

Timeline
31 August 2016
Primary endpoint
31 October 2016
31 October 2016

Quick facts

Lead sponsorOculeve, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposeother
Enrollment27
Start date31 August 2016
Primary completion31 October 2016
Estimated completion31 October 2016

Drugs / interventions tested

Conditions studied

Sponsor

Oculeve, Inc.

Who can join

22 and older, any sex, with Dry Eye or Dry Eye Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones Schirmer test in participants with dry eye disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

Other Oculeve, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02970799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing